Sophia Genetics

SOPHiA GENETICS Publishes Environmental, Social and Governance Impact Summary

BOSTON, United States and LAUSANNE, Switzerland, June 15, 2022 — SOPHiA GENETICS SA (Nasdaq: SOPH) (“the Company”), today announced that the Company has published its first Environmental, Social and Governance Impact Summary (“ESG Impact Summary”). The ESG Impact Summary highlights the Company’s policies, ongoing practices, and recent initiatives across a range of areas including innovation and …

SOPHiA GENETICS Publishes Environmental, Social and Governance Impact Summary Read More »

SOPHiA GENETICS Launches New Solution to Advance Chronic Lymphocytic Leukemia Care, in Collaboration with IDIBAPS

BOSTON, United States and LAUSANNE, Switzerland, June 9, 2022 — SOPHiA GENETICS (Nasdaq: SOPH), the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) of Barcelona, and the Spanish Diagnóstica Longwood today announced from the European Hematology Association Congress in Vienna that they have combined their expertise to develop a new Chronic Lymphocytic Leukemia (CLL) solution to …

SOPHiA GENETICS Launches New Solution to Advance Chronic Lymphocytic Leukemia Care, in Collaboration with IDIBAPS Read More »

SOPHiA GENETICS Provides an Update on its DEEP-Lung-IV Multimodal Clinical Study at ASCO 2022

Study leverages deep learning-enabled analysis of the aggregation of real-world multimodal data to validate predictive signatures associated with response to immunotherapy and prognosis of patients with stage IV non-small cell lung cancer Nearly 20 participating sites activated worldwide with over 500 patients recruited to date. Early findings conceptually validate the potential for multimodal signatures to …

SOPHiA GENETICS Provides an Update on its DEEP-Lung-IV Multimodal Clinical Study at ASCO 2022 Read More »

SOPHiA GENETICS Announces Three Poster Presentations and One Online Publication Accepted at the 2022 American Society of Clinical Oncology Annual (ASCO) Meeting

BOSTON, United States and LAUSANNE, Switzerland – May 31, 2022 – SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, today announced three abstracts accepted for poster presentation and one for online publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7 in Chicago. SOPHiA GENETICS and GE Healthcare will also …

SOPHiA GENETICS Announces Three Poster Presentations and One Online Publication Accepted at the 2022 American Society of Clinical Oncology Annual (ASCO) Meeting Read More »

SOPHiA GENETICS Reports Financial Results for the First Quarter of Fiscal 2022

Steady Start to 2022; FY 2022 Constant Currency Revenue Growth Guidance Reaffirmed BOSTON, United States and LAUSANNE, Switzerland, May 10, 2022 — SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2022. Recent Highlights Revenue for the first quarter of 2022 was $10.9 million, …

SOPHiA GENETICS Reports Financial Results for the First Quarter of Fiscal 2022 Read More »

SOPHiA GENETICS Announces Nomination of Jean-Michel Cosséry to Board of Directorsm

BOSTON, United States and LAUSANNE, Switzerland – May 5, 2022 – SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, today announced the nomination of Jean-Michel Cosséry to its Board of Directors. The Board of Directors will propose the appointment of Mr. Cosséry as a member of the Board of Directors and a member of the Compensation Committee …

SOPHiA GENETICS Announces Nomination of Jean-Michel Cosséry to Board of Directorsm Read More »

SOPHiA GENETICS Hits Milestone of One Million Genomic Profiles Analyzed by the SOPHiA DDM™ Platform

BOSTON, United States and LAUSANNE, Switzerland – April 26, 2022 – SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, has reached the milestone of one million genomic profiles analyzed by its SOPHiA DDM™ Platform, securing its position as one of the largest knowledge sharing platforms connecting thousands of healthcare professionals and researchers across more than 70 countries. Founded …

SOPHiA GENETICS Hits Milestone of One Million Genomic Profiles Analyzed by the SOPHiA DDM™ Platform Read More »

SOPHiA GENETICS Reports Fourth Quarter and Full Year 2021 Financial Results

Revenues Grew 40% for the Fourth Quarter and 42% for Full Year 20212022 Guidance Reaffirmed BOSTON, United States and LAUSANNE, Switzerland, March 15, 2022 — SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today reported financial results for the fourth quarter and full year ended December 31, 2021. Recent Highlights Revenue for full year …

SOPHiA GENETICS Reports Fourth Quarter and Full Year 2021 Financial Results Read More »

SOPHiA GENETICS to Announce Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022

BOSTON and LAUSANNE, Switzerland, Feb 16, 2022 — SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full year 2021 before U.S. markets open on Tuesday, March 15, 2022. SOPHiA will host a conference call and live webcast to discuss its financial results …

SOPHiA GENETICS to Announce Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022 Read More »

SOPHiA GENETICS and REALM IDx Sign Letter of Intent to Collaborate in Accelerating Cancer Research

The intended collaboration aims to help improve patient care by enhancing next-generation sequencing research for cancer care and expanding data sources for precision medicine. BOSTON & ALISO VIEJO, Calif., United States and LAUSANNE, Switzerland – March 14, 2022 – SOPHiA GENETICS (Nasdaq: SOPH) and REALM IDx announced today that they signed a letter of intent to collaborate …

SOPHiA GENETICS and REALM IDx Sign Letter of Intent to Collaborate in Accelerating Cancer Research Read More »